Results 201 to 210 of about 30,729 (226)

Tolerability and Safety of Sustained-Release Bupropion in the Management of Smoking Cessation

Drugs, 2012
Henri-Jean Aubin
exaly  

Bupropion

Reactions Weekly, 2003
openaire   +2 more sources

CYP2B6 Genotype Alters Abstinence Rates in a Bupropion Smoking Cessation Trial

Biological Psychiatry, 2007
Larry Hawk, Leonard H Epstein, Rachel F Tyndale   +2 more
exaly  

Varenicline, an α4β2 Nicotinic Acetylcholine Receptor Partial Agonist, vs Sustained-Release Bupropion and Placebo for Smoking Cessation: A Randomized Controlled Trial

, 2006
D. Gonzales, S. Rennard, M. Nides, C. Oncken, S. Azoulay, C. B. Billing, Watsky Eric Jacob, J. Gong, K. Williams, K. Reeves   +9 more
semanticscholar   +1 more source

Bupropion occupancy of the dopamine transporter is low during clinical treatment

Psychopharmacology, 2002
Bruce K Christensen, Jeffrey H. Meyer
exaly  

Stereoselective Metabolism of Bupropion by Cytochrome P4502B6 (CYP2B6) and Human Liver Microsomes

Pharmaceutical Research, 2008
Evan D Kharasch
exaly  

Bupropion SR vs. Placebo for Weight Loss in Obese Patients with Depressive Symptoms

Obesity, 2002
Thomas A Wadden, Kishore M Gadde, David B. Allison   +2 more
exaly  

Pharmacokinetic Optimisation of Sustained-Release Bupropion for Smoking Cessation

Drugs, 2012
J Andrew Johnston
exaly  

Bupropion

Reactions Weekly, 2009
openaire   +1 more source

Mechanistic Approach for Toxic Effects of Bupropion in Primary Rat Hepatocytes

Drug Research, 2017
E. Ahmadian, H. Babaei, Alireza Mohajjel Nayebi, A. Eftekhari, M. Eghbal   +4 more
semanticscholar   +1 more source